Tuesday, April 17, 2012

new cures on the way for nuerological diseases

today a facebook friend posted this webpage sounds very interesting
here the original webpage in italian and the translation is underneed

Published today in PLoS ONE study conducted by researchers at ISS that sheds light on the mechanism underlying the effects of CnF1 on the brain and opens new scenarios in the fight against rare diseases
They open new scenarios in the fight with Rett syndrome, severe neurodevelopmental disease for which there is still no cure. It is in fact yesterday's publication in the journal PLoS ONE study, conducted by researchers from the Departments of Medicine and Cell Biology and Neuroscience Institute of Health, which highlighted one of the mechanisms underlying the activity of a toxin produced by bacterium Escherichia coli (the CnF1) on the plasticity of the nervous system.
"The results were encouraging - ISS said the President, Professor Henry Garaci - they open up the possibility of a therapeutic application of the toxin CnF1 in Rett syndrome but also in other rare diseases with cognitive and motor deficits. More recent studies have led to the first in vivo demonstration of the role of this drug and thus have a greater translational relevance. "
In the study published today in PLoS ONE shows how the treatment with the CnF1 of astrocytes (glial cells has always been considered as "handmaids" of neurons but whose role in brain function is gradually revaluing) is able to promote the in vitro growth ofneurons cultured on their side and synapse formation (synaptogenesis).
The action at the level of the astrocytic CnF1 constitutes an important feature of this protein molecule, for making it a valuable tool in the development of targeted therapies not only for the Rett syndrome but also for all those characterized by abnormal astrocyte.As with other substances produced by microbial species (consider, for example, the botulinum neurotoxin, which ranges from cosmetics applied to the muscle pathology and treatment of diseases algiche), the toxin of Escherichia coli confirms that the action at the cellular level natural products such as toxins of bacterial origin can have very important implications in the medical field.
"The continuation of the research - said Dr Carla Fiorentini, coordinator of the multidisciplinary group that studies the ISS CnF1 - includes the study of the effects of this toxin in other animal models, both of neurodegenerative disorders such as Alzheimer's, both of alterations neurodevelopment, are associated with intellectual disability and / or motor. Crucial and final goal of our studies is obviously the start of the trial in humans.The latter necessitates the synthesis of CnF1 according to Good Manufacturing Practice and carrying out the various procedures necessary for the request for authorization of a phase I study of the product by accredited laboratories. "
The study confirms the key role of the toxin, which emerged in a paper published a few weeks ago on Neuropsychopharmacology: in this case the ISS researchers have shown that in transgenic mice, a model for Rett syndrome, the toxin is able to fight the changes in layer of astrocytes as well as cognitive problems and motor coordination deficits typical of the disease.

No comments:

Post a Comment